Controlled Substances: Final Revised Aggregate Production Quotas for 2005, 68088-68090 [05-22287]
Download as PDF
<![CDATA[
68088
Federal Register / Vol. 70, No. 216 / Wednesday, November 9, 2005 / Notices
States Attorney for the Southern District
of Indiana, 10 West Market, Suite 2100,
Indianapolis, Indiana 46204, and at U.S.
EPA Region 5, 77 West Jackson
Boulevard, Chicago, IL 60604. During
the public comment period, the consent
decrees may also be examined on the
following Department of Justice Web
site, https://www.usdoj.gov/enrd/
open.html. A copy of the Consent
Decree may also be obtained by mail
from the Consent Decree Library, P.O.
Box 7611, U.S. Department of Justice,
Washington, DC 20044–7611, or by
faxing a request to Tonia Fleetwood, fax
no. (202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy, please refer to the referenced case
and enclose a check in the amount of
$18.25 (25 cents per page reproduction
costs), payable to the U.S. Treasury.
William D. Brighton,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. 05–22362 Filed 11–8–05; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–259F]
Controlled Substances: Final Revised
Aggregate Production Quotas for 2005
Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Notice of final aggregate
production quotas for 2005.
AGENCY:
This notice establishes final
2005 aggregate production quotas for
controlled substances in Schedules I
and II of the Controlled Substances Act
(CSA). The DEA has taken into
consideration comments received in
response to a notice of the proposed
revised aggregate production quotas for
2005 published August 5, 2005 (70 FR
45432).
EFFECTIVE DATE: November 9, 2005.
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section,
Drug Enforcement Administration,
Washington, DC 20537, Telephone:
(202) 307–7183.
SUPPLEMENTARY INFORMATION: Section
306 of the CSA (21 U.S.C. 826) requires
that the Attorney General establish
aggregate production quotas for each
basic class of controlled substance listed
in Schedules I and II. This
responsibility has been delegated to the
Administrator of the DEA by 28 CFR
SUMMARY:
VerDate jul<14>2003
16:18 Nov 08, 2005
Jkt 208001
0.100. The Administrator, in turn, has
redelegated this function to the Deputy
Administrator, pursuant to 28 CFR
0.104.
The 2005 aggregate production quotas
represent those quantities of controlled
substances in Schedules I and II that
may be produced in the United States in
2005 to provide adequate supplies of
each substance for: The estimated
medical, scientific, research and
industrial needs of the United States;
lawful export requirements; and the
establishment and maintenance of
reserve stocks (21 U.S.C. 826(a) and 21
CFR 1303.11). These quotas do not
include imports of controlled
substances.
On August 5, 2005, a notice of the
proposed revised 2005 aggregate
production quotas for certain controlled
substances in Schedules I and II was
published in the Federal Register (70
FR 45432). All interested persons were
invited to comment on or object to these
proposed aggregate production quotas
on or before August 26, 2005.
Nine companies commented on a total
of 21 Schedules I and II controlled
substances within the published
comment period. One company
questioned the aggregate production
quota for marihuana. Eight companies
proposed the aggregate production
quotas for alfentanil, amphetamine,
codeine (for conversion), difenoxin,
dihydromorphine, diphenoxylate,
fentanyl, hydrocodone, hydromorphone,
levo-desoxyephedrine, methadone,
methadone intermediate,
methylphenidate, morphine (for sale),
oxycodone, pentobarbital, remifentanil,
sufentanil, tetrahydrocannabinols, and
thebaine were insufficient to provide for
the estimated medical, scientific,
research, and industrial needs of the
United States, for export requirements
and for the establishment and
maintenance of reserve stocks.
DEA has taken into consideration the
above comments along with the relevant
2004 year-end inventories, initial 2005
manufacturing quotas, 2005 export
requirements, actual and projected 2005
sales, research, product development
requirements and additional
applications received. Based on this
information, the DEA has adjusted the
final 2005 aggregate production quotas
for alfentanil, cathinone,
dihydromorphine, diphenoxylate, levoalphacetylmethadol, levodesoxyephedrine, methadone,
methadone intermediate, oxycodone,
pentobarbital and sufentanil to meet the
legitimate needs of the United States.
Regarding amphetamine, codeine (for
conversion), difenoxin, fentanyl,
hydrocodone, hydromorphone,
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
marihuana, methylphenidate, morphine
(for sale), remifentanil,
tetrahydrocannabinols and thebaine the
DEA has determined that the proposed
revised 2005 aggregate production
quotas are sufficient to meet the current
2005 estimated medical, scientific,
research, and industrial needs of the
United States and to provide for
adequate inventories.
Therefore, under the authority vested
in the Attorney General by section 306
of the Controlled Substances Act of
1970 (21 U.S.C. 826), and delegated to
the Administrator of the DEA by § 0.100
of Title 28 of the Code of Federal
Regulations, and redelegated to the
Deputy Administrator, pursuant to
§ 0.104 of Title 28 of the Code of Federal
Regulations, the Deputy Administrator
hereby orders that the 2005 final
aggregate production quotas for the
following controlled substances,
expressed in grams of anhydrous acid or
base, be established as follows:
Basic Class—Schedule I
2,5–Dimethoxyamphetamine
2,5–Dimethoxy-4ethylamphetamine (DOET)
2,5–Dimethoxy-4-(n)propylthiophenethylamine
3–Methylfentanyl ...................
3–Methylthiofentanyl .............
3,4–
Methylenedioxyamphetamine (MDA) ..........................
3,4–Methylenedioxy-Nethylamphetamine (MDEA)
3,4–
Methylenedioxymethamphetamine (MDMA) ...............
3,4,5–
Trimethoxyamphetamine ...
4–Bromo-2,5dimethoxyamphetamine
(DOB) ................................
4–Bromo-2,5dimethoxyphenethylamine
(2–CB) ...............................
4–Methoxyamphetamine ......
4–Methylaminorex ................
4–Methyl-2,5dimethoxyamphetamine
(DOM) ...............................
5–Methoxy-3,4methylenedioxyamphetamine .....................................
5–Methoxy-N,Ndiisopropyltryptamine (5–
MeO-DIPT) ........................
Acetyl-alpha-methylfentanyl ..
Acetyldihydrocodeine ............
Acetylmethadol .....................
Allylprodine ...........................
Alphacetylmethadol ..............
Alpha-ethyltryptamine ...........
Alphameprodine ....................
Alphamethadol ......................
Alpha-methyltryptamine
(AMT) ................................
E:\FR\FM\09NON1.SGM
pfrm13
PsN: 09NON1
Final Revised
2005 Quotas
(g)
2,801,000
2
10
2
2
15
5
17
2
2
2
5
2
2
2
10
2
2
2
2
2
2
2
3
10
68089
Federal Register / Vol. 70, No. 216 / Wednesday, November 9, 2005 / Notices
Basic Class—Schedule I
Alpha-methylfentanyl ............
Alpha-methylthiofentanyl ......
Aminorex ...............................
Benzylmorphine ....................
Betacetylmethadol ................
Beta-hydroxy-3methylfentanyl ...................
Beta-hydroxyfentanyl ............
Betameprodine .....................
Betamethadol ........................
Betaprodine ..........................
Bufotenine .............................
Cathinone .............................
Codeine-N-oxide ...................
Diethyltryptamine ..................
Difenoxin ...............................
Dihydromorphine ..................
Final Revised
2005 Quotas
(g)
2
2
2
2
2
2
2
2
2
2
2
3
252
2
5,000
2,046,000
Basic Class—Schedule I
Dimethyltryptamine ...............
Gamma-hydroxybutyric acid
Heroin ...................................
Hydromorphinol ....................
Hydroxypethidine ..................
Lysergic acid diethylamide
(LSD) .................................
Marihuana .............................
Mescaline ..............................
Methaqualone .......................
Methcathinone ......................
Methyldihydromorphine ........
Morphine-N-oxide .................
N,N-Dimethylamphetamine ...
N-Ethylamphetamine ............
Final Revised
2005 Quotas
(g)
3
8,000,000
2
2
2
61
4,500,000
2
5
4
2
252
2
2
N-Hydroxy-3,4methylenedioxyamphetamine .....................................
Noracymethadol ....................
Norlevorphanol .....................
Normethadone ......................
Normorphine .........................
Para-fluorofentanyl ...............
Phenomorphan .....................
Pholcodine ............................
Propiram ...............................
Psilocybin ..............................
Psilocyn ................................
Tetrahydrocannabinols .........
Thiofentanyl ..........................
Trimeperidine ........................
1–Phenylcyclohexylamine ..............................................................................................................................................................
Alfentanil ........................................................................................................................................................................................
Alphaprodine ..................................................................................................................................................................................
Amobarbital ....................................................................................................................................................................................
Amphetamine .................................................................................................................................................................................
Cocaine ..........................................................................................................................................................................................
Codeine (for sale) ..........................................................................................................................................................................
Codeine (for conversion) ...............................................................................................................................................................
Dextropropoxyphene ......................................................................................................................................................................
Dihydrocodeine ..............................................................................................................................................................................
Diphenoxylate ................................................................................................................................................................................
Ecgonine ........................................................................................................................................................................................
Ethylmorphine ................................................................................................................................................................................
Fentanyl .........................................................................................................................................................................................
Glutethimide ...................................................................................................................................................................................
Hydrocodone (for sale) ..................................................................................................................................................................
Hydrocodone (for conversion) .......................................................................................................................................................
Hydromorphone .............................................................................................................................................................................
Isomethadone ................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ..................................................................................................................................................
Levomethorphan ............................................................................................................................................................................
Levorphanol ...................................................................................................................................................................................
Meperidine .....................................................................................................................................................................................
Metazocine .....................................................................................................................................................................................
Methadone (for sale) .....................................................................................................................................................................
Methadone Intermediate ................................................................................................................................................................
Methamphetamine [700,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,615,000
grams for methamphetamine mostly for conversion to a Schedule III product; and 45,000 grams for methamphetamine
(for sale)] ....................................................................................................................................................................................
Methylphenidate .............................................................................................................................................................................
Morphine (for sale) ........................................................................................................................................................................
Morphine (for conversion) ..............................................................................................................................................................
Nabilone .........................................................................................................................................................................................
Noroxymorphone (for sale) ............................................................................................................................................................
Noroxymorphone (for conversion) .................................................................................................................................................
Opium ............................................................................................................................................................................................
Oxycodone (for sale) .....................................................................................................................................................................
Oxycodone (for conversion) ..........................................................................................................................................................
Oxymorphone ................................................................................................................................................................................
Pentobarbital ..................................................................................................................................................................................
Phencyclidine .................................................................................................................................................................................
Phenmetrazine ...............................................................................................................................................................................
Racemethorphan ...........................................................................................................................................................................
Remifentanil ...................................................................................................................................................................................
Secobarbital ...................................................................................................................................................................................
Sufentanil .......................................................................................................................................................................................
Thebaine ........................................................................................................................................................................................
16:18 Nov 08, 2005
Jkt 208001
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
2
2
52
2
12
2
2
2
50,000
2
7
312,500
2
2
Proposed Revised
2005 Quotas
(g)
Basic Class—Schedule II
VerDate jul<14>2003
Final Revised
2005 Quotas
(g)
Basic Class—Schedule I
E:\FR\FM\09NON1.SGM
pfrm13
PsN: 09NON1
2
2,800
2
2
14,500,000
228,000
39,605,000
55,000,000
167,365,000
750,000
833,000
73,000
2
1,428,000
2
37,604,000
1,500,000
3,300,000
2
3
2
5,000
9,753,000
1
17,940,000
20,334,000
2,360,000
35,000,000
35,000,000
110,774,000
2
1,002
4,000,000
1,280,000
50,490,000
920,000
534,000
20,335,000
2,006
2
2
1,800
2
4,500
72,453,000
68090
Federal Register / Vol. 70, No. 216 / Wednesday, November 9, 2005 / Notices
The Deputy Administrator further
orders that aggregate production quotas
for all other Schedules I and II
controlled substances included in
§§ 1308.11 and 1308.12 of Title 21 of the
Code of Federal Regulations remain at
zero.
The Office of Management and Budget
has determined that notices of aggregate
production quotas are not subject to
centralized review under Executive
Order 12866.
This action does not preempt or
modify any provision of state law; nor
does it impose enforcement
responsibilities on any state; nor does it
diminish the power of any state to
enforce its own laws. Accordingly, this
action does not have federalism
implications warranting the application
of Executive Order 13132.
The Deputy Administrator hereby
certifies that this action will have no
significant impact upon small entities
whose interests must be considered
under the Regulatory Flexibility Act, 5
U.S.C. 601 et seq. The establishment of
aggregate production quotas for
Schedules I and II controlled substances
is mandated by law and by international
treaty obligations. The quotas are
necessary to provide for the estimated
medical, scientific, research and
industrial needs of the United States, for
export requirements and the
establishment and maintenance of
reserve stocks. While aggregate
production quotas are of primary
importance to large manufacturers, their
impact upon small entities is neither
negative nor beneficial. Accordingly, the
Deputy Administrator has determined
that this action does not require a
regulatory flexibility analysis.
This action meets the applicable
standards set forth in sections 3(a) and
3(b)(2) of Executive Order 12988 Civil
Justice Reform.
This action will not result in the
expenditure by State, local, and tribal
governments, in the aggregate, or by the
private sector, of $117,000,000 or more
in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions were
deemed necessary under the provisions
of the Unfunded Mandates Reform Act
of 1995.
This action is not a major rule as
defined by section 804 of the Small
Business Regulatory Enforcement
Fairness Act of 1996. This action will
not result in an annual effect on the
economy of $100,000,000 or more; a
major increase in costs or prices; or
significant adverse effects on
competition, employment, investment,
productivity, innovation, or on the
ability of United States-based
VerDate jul<14>2003
16:18 Nov 08, 2005
Jkt 208001
companies to compete with foreignbased companies in domestic and
export markets.
Dated: November 3, 2005.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05–22287 Filed 11–8–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
Agency Information Collection
Activities: Proposed Collection;
Comments Requested
30-Day Notice of Information
Collection Under Review 2006 Census
of Adult Parole Supervising Agencies.
ACTION:
The Department of Justice (DOJ),
Office of Justice Programs (OJP) has
submitted the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies. This
proposed information collection was
previously published in the Federal
Register Volume 70, Number 161, page
48981 on August 22, 2005, allowing for
a 60 day comment period.
The purpose of this notice is to allow
for an additional 30 days for public
comment until December 9, 2005. This
process is conducted in accordance with
5 CFR 1320.10.
Written comments and/or suggestions
regarding the items contained in this
notice, especially the estimated public
burden and associated response time,
should be directed to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Washington, DC 20503.
Additionally, comments may be
submitted to OMB via facsimile to (202)
395–5806. Written comments and
suggestions from the public and affected
agencies concerning the proposed
collection of information are
encouraged. Your comments should
address one or more of the following
four points:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Reinstatement, with change, of a
previously approved collection for
which approval has expired.
(2) Title of the Form/Collection: 2006
Census of Adult Parole Supervising
Agencies.
(3) Agency form number, if any, and
the applicable component of the
Department sponsoring the collection:
Form: CJ–36. Corrections Statistics,
Bureau of Justice Statistics, Office of
Justice Programs, United States
Department of Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: State Departments of
Corrections or State Parole authority.
Others: The Federal Bureau of Prisons.
For the CJ–36 form, 54 central reporters
(two State jurisdictions in California
and one each from the remaining States,
the District of Columbia, the Federal
Bureau of Prisons, and one local
authority) responsible for keeping
records on parolees will be asked to
provide information for the following
categories:
(a) Whether the parole agency is
located within the executive or judicial
branch of government, whether it is a
private organization under contract to a
government agency; and whether the
agency is administered by the
Department of Corrections, a court, an
independent agency or another parole
agency;
(b) As of June 30, 2006, the number
of adult parolees under their
jurisdiction;
(c) As of June 30, 2006, the number
of adult parolees under their
jurisdiction who were supervised
following a discretionary release, a
mandatory release, a special conditional
release, or other type of release from
prison;
(d) Whether the adult parole
supervising agency also supervises
either adult probationers or juveniles on
probation or parole/aftercare, and the
E:\FR\FM\09NON1.SGM
pfrm13
PsN: 09NON1
]]>Agencies
[Federal Register Volume 70, Number 216 (Wednesday, November 9, 2005)]
[Notices]
[Pages 68088-68090]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-22287]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-259F]
Controlled Substances: Final Revised Aggregate Production Quotas
for 2005
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Notice of final aggregate production quotas for 2005.
-----------------------------------------------------------------------
SUMMARY: This notice establishes final 2005 aggregate production quotas
for controlled substances in Schedules I and II of the Controlled
Substances Act (CSA). The DEA has taken into consideration comments
received in response to a notice of the proposed revised aggregate
production quotas for 2005 published August 5, 2005 (70 FR 45432).
EFFECTIVE DATE: November 9, 2005.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826)
requires that the Attorney General establish aggregate production
quotas for each basic class of controlled substance listed in Schedules
I and II. This responsibility has been delegated to the Administrator
of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated
this function to the Deputy Administrator, pursuant to 28 CFR 0.104.
The 2005 aggregate production quotas represent those quantities of
controlled substances in Schedules I and II that may be produced in the
United States in 2005 to provide adequate supplies of each substance
for: The estimated medical, scientific, research and industrial needs
of the United States; lawful export requirements; and the establishment
and maintenance of reserve stocks (21 U.S.C. 826(a) and 21 CFR
1303.11). These quotas do not include imports of controlled substances.
On August 5, 2005, a notice of the proposed revised 2005 aggregate
production quotas for certain controlled substances in Schedules I and
II was published in the Federal Register (70 FR 45432). All interested
persons were invited to comment on or object to these proposed
aggregate production quotas on or before August 26, 2005.
Nine companies commented on a total of 21 Schedules I and II
controlled substances within the published comment period. One company
questioned the aggregate production quota for marihuana. Eight
companies proposed the aggregate production quotas for alfentanil,
amphetamine, codeine (for conversion), difenoxin, dihydromorphine,
diphenoxylate, fentanyl, hydrocodone, hydromorphone, levo-
desoxyephedrine, methadone, methadone intermediate, methylphenidate,
morphine (for sale), oxycodone, pentobarbital, remifentanil,
sufentanil, tetrahydrocannabinols, and thebaine were insufficient to
provide for the estimated medical, scientific, research, and industrial
needs of the United States, for export requirements and for the
establishment and maintenance of reserve stocks.
DEA has taken into consideration the above comments along with the
relevant 2004 year-end inventories, initial 2005 manufacturing quotas,
2005 export requirements, actual and projected 2005 sales, research,
product development requirements and additional applications received.
Based on this information, the DEA has adjusted the final 2005
aggregate production quotas for alfentanil, cathinone, dihydromorphine,
diphenoxylate, levo-alphacetylmethadol, levo-desoxyephedrine,
methadone, methadone intermediate, oxycodone, pentobarbital and
sufentanil to meet the legitimate needs of the United States.
Regarding amphetamine, codeine (for conversion), difenoxin,
fentanyl, hydrocodone, hydromorphone, marihuana, methylphenidate,
morphine (for sale), remifentanil, tetrahydrocannabinols and thebaine
the DEA has determined that the proposed revised 2005 aggregate
production quotas are sufficient to meet the current 2005 estimated
medical, scientific, research, and industrial needs of the United
States and to provide for adequate inventories.
Therefore, under the authority vested in the Attorney General by
section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826),
and delegated to the Administrator of the DEA by Sec. 0.100 of Title
28 of the Code of Federal Regulations, and redelegated to the Deputy
Administrator, pursuant to Sec. 0.104 of Title 28 of the Code of
Federal Regulations, the Deputy Administrator hereby orders that the
2005 final aggregate production quotas for the following controlled
substances, expressed in grams of anhydrous acid or base, be
established as follows:
------------------------------------------------------------------------
Final Revised
Basic Class--Schedule I 2005 Quotas
(g)
------------------------------------------------------------------------
2,5-Dimethoxyamphetamine................................ 2,801,000
2,5-Dimethoxy-4-ethylamphetamine (DOET)................. 2
2,5-Dimethoxy-4-(n)-propylthiophenethylamine............ 10
3-Methylfentanyl........................................ 2
3-Methylthiofentanyl.................................... 2
3,4-Methylenedioxyamphetamine (MDA)..................... 15
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)............ 5
3,4-Methylenedioxymethamphetamine (MDMA)................ 17
3,4,5-Trimethoxyamphetamine............................. 2
4-Bromo-2,5-dimethoxyamphetamine (DOB).................. 2
4-Bromo-2,5-dimethoxyphenethylamine (2-CB).............. 2
4-Methoxyamphetamine.................................... 5
4-Methylaminorex........................................ 2
4-Methyl-2,5-dimethoxyamphetamine (DOM)................. 2
5-Methoxy-3,4-methylenedioxyamphetamine................. 2
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)........ 10
Acetyl-alpha-methylfentanyl............................. 2
Acetyldihydrocodeine.................................... 2
Acetylmethadol.......................................... 2
Allylprodine............................................ 2
Alphacetylmethadol...................................... 2
Alpha-ethyltryptamine................................... 2
Alphameprodine.......................................... 2
Alphamethadol........................................... 3
Alpha-methyltryptamine (AMT)............................ 10
[[Page 68089]]
Alpha-methylfentanyl.................................... 2
Alpha-methylthiofentanyl................................ 2
Aminorex................................................ 2
Benzylmorphine.......................................... 2
Betacetylmethadol....................................... 2
Beta-hydroxy-3-methylfentanyl........................... 2
Beta-hydroxyfentanyl.................................... 2
Betameprodine........................................... 2
Betamethadol............................................ 2
Betaprodine............................................. 2
Bufotenine.............................................. 2
Cathinone............................................... 3
Codeine-N-oxide......................................... 252
Diethyltryptamine....................................... 2
Difenoxin............................................... 5,000
Dihydromorphine......................................... 2,046,000
Dimethyltryptamine...................................... 3
Gamma-hydroxybutyric acid............................... 8,000,000
Heroin.................................................. 2
Hydromorphinol.......................................... 2
Hydroxypethidine........................................ 2
Lysergic acid diethylamide (LSD)........................ 61
Marihuana............................................... 4,500,000
Mescaline............................................... 2
Methaqualone............................................ 5
Methcathinone........................................... 4
Methyldihydromorphine................................... 2
Morphine-N-oxide........................................ 252
N,N-Dimethylamphetamine................................. 2
N-Ethylamphetamine...................................... 2
N-Hydroxy-3,4-methylenedioxyamphetamine................. 2
Noracymethadol.......................................... 2
Norlevorphanol.......................................... 52
Normethadone............................................ 2
Normorphine............................................. 12
Para-fluorofentanyl..................................... 2
Phenomorphan............................................ 2
Pholcodine.............................................. 2
Propiram................................................ 50,000
Psilocybin.............................................. 2
Psilocyn................................................ 7
Tetrahydrocannabinols................................... 312,500
Thiofentanyl............................................ 2
Trimeperidine........................................... 2
------------------------------------------------------------------------
------------------------------------------------------------------------
Proposed Revised
Basic Class--Schedule II 2005 Quotas (g)
------------------------------------------------------------------------
1-Phenylcyclohexylamine.............................. 2
Alfentanil........................................... 2,800
Alphaprodine......................................... 2
Amobarbital.......................................... 2
Amphetamine.......................................... 14,500,000
Cocaine.............................................. 228,000
Codeine (for sale)................................... 39,605,000
Codeine (for conversion)............................. 55,000,000
Dextropropoxyphene................................... 167,365,000
Dihydrocodeine....................................... 750,000
Diphenoxylate........................................ 833,000
Ecgonine............................................. 73,000
Ethylmorphine........................................ 2
Fentanyl............................................. 1,428,000
Glutethimide......................................... 2
Hydrocodone (for sale)............................... 37,604,000
Hydrocodone (for conversion)......................... 1,500,000
Hydromorphone........................................ 3,300,000
Isomethadone......................................... 2
Levo-alphacetylmethadol (LAAM)....................... 3
Levomethorphan....................................... 2
Levorphanol.......................................... 5,000
Meperidine........................................... 9,753,000
Metazocine........................................... 1
Methadone (for sale)................................. 17,940,000
Methadone Intermediate............................... 20,334,000
Methamphetamine [700,000 grams of levo- 2,360,000
desoxyephedrine for use in a non-controlled, non-
prescription product; 1,615,000 grams for
methamphetamine mostly for conversion to a Schedule
III product; and 45,000 grams for methamphetamine
(for sale)].........................................
Methylphenidate...................................... 35,000,000
Morphine (for sale).................................. 35,000,000
Morphine (for conversion)............................ 110,774,000
Nabilone............................................. 2
Noroxymorphone (for sale)............................ 1,002
Noroxymorphone (for conversion)...................... 4,000,000
Opium................................................ 1,280,000
Oxycodone (for sale)................................. 50,490,000
Oxycodone (for conversion)........................... 920,000
Oxymorphone.......................................... 534,000
Pentobarbital........................................ 20,335,000
Phencyclidine........................................ 2,006
Phenmetrazine........................................ 2
Racemethorphan....................................... 2
Remifentanil......................................... 1,800
Secobarbital......................................... 2
Sufentanil........................................... 4,500
Thebaine............................................. 72,453,000
------------------------------------------------------------------------
[[Page 68090]]
The Deputy Administrator further orders that aggregate production
quotas for all other Schedules I and II controlled substances included
in Sec. Sec. 1308.11 and 1308.12 of Title 21 of the Code of Federal
Regulations remain at zero.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866.
This action does not preempt or modify any provision of state law;
nor does it impose enforcement responsibilities on any state; nor does
it diminish the power of any state to enforce its own laws.
Accordingly, this action does not have federalism implications
warranting the application of Executive Order 13132.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq.
The establishment of aggregate production quotas for Schedules I and II
controlled substances is mandated by law and by international treaty
obligations. The quotas are necessary to provide for the estimated
medical, scientific, research and industrial needs of the United
States, for export requirements and the establishment and maintenance
of reserve stocks. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
This action meets the applicable standards set forth in sections
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This action will not result in the expenditure by State, local, and
tribal governments, in the aggregate, or by the private sector, of
$117,000,000 or more in any one year, and will not significantly or
uniquely affect small governments. Therefore, no actions were deemed
necessary under the provisions of the Unfunded Mandates Reform Act of
1995.
This action is not a major rule as defined by section 804 of the
Small Business Regulatory Enforcement Fairness Act of 1996. This action
will not result in an annual effect on the economy of $100,000,000 or
more; a major increase in costs or prices; or significant adverse
effects on competition, employment, investment, productivity,
innovation, or on the ability of United States-based companies to
compete with foreign-based companies in domestic and export markets.
Dated: November 3, 2005.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05-22287 Filed 11-8-05; 8:45 am]
BILLING CODE 4410-09-P
